Study Summary
This trial aims to test a drug to treat worsening heart failure in adults with normal heart function.
- Diastolic Heart Failure
- Heart Failure
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: Baseline, Week 26
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
LY3540378 Dose 1
1 of 4
LY3540378 Dose 2
1 of 4
LY3540378 Dose 3
1 of 4
Placebo
1 of 4
Experimental Treatment
Non-Treatment Group
432 Total Participants · 4 Treatment Groups
Primary Treatment: LY3540378 Dose 1 · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many healthcare facilities are participating in this trial?
"Both North York Diagnostic and Cardiac Centre in North York, Ontario and Fadia El Boreky Medicine in Waterloo, California are participating sites for this research trial. The University of Texas Medical Branch located in Galveston, Pennsylvania is also enrolling patients along with 24 other medical facilities." - Anonymous Online Contributor
Is this investigation actively seeking participants?
"As indicated on clinicaltrials.gov, the slated participants for this medical trial are not currently being recruited. Initially posted in November of 2022 and last updated two weeks prior, 701 other trials remain open to new patients at present." - Anonymous Online Contributor
Has the Federal Drug Administration sanctioned LY3540378 Dose 1?
"Our experts at Power gave LY3540378 Dose 1 a rating of 2 on the safety scale, as Phase 2 trials have yet to yield data demonstrating efficacy." - Anonymous Online Contributor